Sanofi and Teva's Collaboration Ignites Competition in IBD Drug Market
TL;DR Summary
Sanofi has secured a deal worth up to $1.5 billion with Teva for the development and launch of Teva's anti-TL1A antibody. Teva will receive an upfront payment of $500 million and up to $1 billion in development and launch milestones. This deal adds fuel to the competition against Merck and Roivant, who are also developing anti-TL1A treatments.
- Updated: Sanofi's $1.5B pact with Teva in IBD adds fuel to anti-TL1A race against Merck, Roivant and Pfizer Endpoints News
- Sanofi pays Teva $500M to join red-hot bowel disease race FierceBiotech
- Teva hopes Sanofi collaboration will lead to blockbuster IBD drug Reuters
- Teva teams with Sanofi on inflammatory bowel treatment Globes
- View Full Coverage on Google News
Reading Insights
Total Reads
0
Unique Readers
1
Time Saved
0 min
vs 1 min read
Condensed
55%
128 → 57 words
Want the full story? Read the original article
Read on Endpoints News